FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* JOHANNESSEN JAN							2. Issuer Name and Ticker or Trading Symbol Twist Bioscience Corp [TWST]										onship of Reporting all applicable) Director		10% Ow		mer
(Last) (First) (Middle) C/O TWIST BIOSCIENCE CORPORATION 681 GATEWAY BLVD.						3. Date of Earliest Transaction (Month/Day/Year) 02/16/2022											below)	(give title		Other (s	
(Street) SOUTH SAN FRANCISCO (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									Lin	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(3)	-																			
1. Title of Security (Instr. 3)				2. Trans Date (Month/	action	ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		<u>.</u>	3. Transaction Code (Instr.					d (A) or	or 5. Amou 4 and Securitie Benefici		nt of s ally following	Form (D) o	n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount		(A) or (D)	Price	Trancac		tion(s)			(1130.4)		
Common Stock 02/10						2022				M		5,000)	A	\$14	1	10,136		D		
Common Stock 02				02/16	5/2022					S ⁽¹⁾		5,000)	D \$59		2	2 5,136		D		
		Т	able II -									sed of onverti				/ Ow	ned			,	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,		Transaction Code (Instr.				6. Date Exercisal Expiration Date (Month/Day/Year			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			Deriv Secu	s. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	te ercisable		xpiration ate	Title	1	Amount or Number of Shares						
Director Stock Option (right to	\$14	02/16/2022			М			5,000		(2)	10	0/29/2028	Comr		5,000		\$0	22,304	4	D	

Explanation of Responses:

- 1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 17, 2021.
- 2. 1/3rd of the shares subject to the option vested and became exercisable on October 30, 2019, and 1/3rd of the shares subject to the option vest and become exercisable on each annual anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

/s/ William Solis, as Attorneyin-Fact for Jan Johannessen

02/18/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.